Biotangents
$2.9M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Biotangents is currently valued at N/A as of November 28, 2024. The company has raised a total of $9.1M in funding.
Investment Perspective
Biotangents's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Biotangents Worth in 2025?
As of 2025, Biotangents is valued at N/A, based on the company's Later Stage VC funding round in November 28, 2024. This valuation positions Biotangents as one of the leading private companies in the sector.
Biotangents Valuation History
Biotangents's funding history demonstrates steady growth and investor confidence.
How Biotangents Valuation is Determined
Private company valuations like Biotangents's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Biotangents Valuation FAQs
Is Biotangents profitable?
Biotangents has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Biotangents's valuation compare to competitors?
Biotangents is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Biotangents IPO?
Biotangents has not announced plans for an initial public offering. Until an IPO, investors can access Biotangents shares through secondary market platforms.